Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2015 1
2016 2
2018 2
2020 3
2021 2
2022 3
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
The Xanthine Oxidase Inhibitor Febuxostat Suppresses Adipogenesis and Activates Nrf2.
Higa Y, Hiasa M, Tenshin H, Nakaue E, Tanaka M, Kim S, Nakagawa M, Shimizu S, Tanimoto K, Teramachi J, Harada T, Oda A, Oura M, Sogabe K, Hara T, Sumitani R, Maruhashi T, Yamagami H, Endo I, Matsumoto T, Tanaka E, Abe M. Higa Y, et al. Among authors: shimizu s. Antioxidants (Basel). 2023 Jan 5;12(1):133. doi: 10.3390/antiox12010133. Antioxidants (Basel). 2023. PMID: 36670994 Free PMC article.
TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma.
Teramachi J, Tenshin H, Hiasa M, Oda A, Bat-Erdene A, Harada T, Nakamura S, Ashtar M, Shimizu S, Iwasa M, Sogabe K, Oura M, Fujii S, Kagawa K, Miki H, Endo I, Haneji T, Matsumoto T, Abe M. Teramachi J, et al. Among authors: shimizu s. Haematologica. 2021 May 1;106(5):1401-1413. doi: 10.3324/haematol.2019.234476. Haematologica. 2021. PMID: 32273474 Free PMC article.
Mechanisms of preferential bone formation in myeloma bone lesions by proteasome inhibitors.
Nakaue E, Teramachi J, Tenshin H, Hiasa M, Harada T, Oda A, Inoue Y, Shimizu S, Higa Y, Sogabe K, Oura M, Hara T, Sumitani R, Maruhashi T, Yamagami H, Endo I, Tanaka E, Abe M. Nakaue E, et al. Among authors: shimizu s. Int J Hematol. 2023 Jul;118(1):88-98. doi: 10.1007/s12185-023-03601-2. Epub 2023 Apr 11. Int J Hematol. 2023. PMID: 37039914 Free PMC article.
The Roles of ROS Generation in RANKL-Induced Osteoclastogenesis: Suppressive Effects of Febuxostat.
Ashtar M, Tenshin H, Teramachi J, Bat-Erdene A, Hiasa M, Oda A, Tanimoto K, Shimizu S, Higa Y, Harada T, Oura M, Sogabe K, Nakamura S, Fujii S, Sumitani R, Miki H, Udaka K, Takahashi M, Kagawa K, Endo I, Tanaka E, Matsumoto T, Abe M. Ashtar M, et al. Among authors: shimizu s. Cancers (Basel). 2020 Apr 9;12(4):929. doi: 10.3390/cancers12040929. Cancers (Basel). 2020. PMID: 32283857 Free PMC article.
TGF-β-activated kinase-1 inhibitor LL-Z1640-2 reduces joint inflammation and bone destruction in mouse models of rheumatoid arthritis by inhibiting NLRP3 inflammasome, TACE, TNF-α and RANKL expression.
Tenshin H, Teramachi J, Ashtar M, Hiasa M, Inoue Y, Oda A, Tanimoto K, Shimizu S, Higa Y, Harada T, Oura M, Sogabe K, Hara T, Sumitani R, Maruhashi T, Sebe M, Tsutsumi R, Sakaue H, Endo I, Matsumoto T, Tanaka E, Abe M. Tenshin H, et al. Among authors: shimizu s. Clin Transl Immunology. 2022 Jan 19;11(1):e1371. doi: 10.1002/cti2.1371. eCollection 2022. Clin Transl Immunology. 2022. PMID: 35079379 Free PMC article.
18 results